Table 1. Summary of cases of breakthrough Trichosporon asahii fungemia in patients with hematologic disease who were receiving antifungal agents (including the present case).

Underlying disease	Predisposing condition	Site of infection	Previous antifungal Tx.	Definite Tx. of trichosporonosis	Outcome	AMB	FLC	ITC	VRC	CAF	MIF	Ref.
Myelodysplastic syndrome	SCT	Catheter	ITC	VRC	Survived	1	8	16	0.5	16		In this case
AML	CTx	Primary fungemia	CAF	L-AMB + VRC	Expired	>32	4	0.5	>0.015	16		[4]
AML	CTx	Primary fungemia	ITC	VRC	Survived	1	32	1	0.5		>16	[5]
Thalassemia	SCT	Catheter	FLC	VRC	Survived	0.25	3		0.04	>32		[9]
AML	CTx	Catheter	FLC	AMB + CAF	Survived	0.06	>64					[13]
Hematologic malignancy	SCT	Primary fungemia	MIF	L-AMB	Survived	S	S	S	S	R	R	[14]
AML	CTx	Catheter	FLC	L-AMB + CAF	Survived							[15]
AML	CTx	GI tract	PSC	VRC + AMB								[17]
AML	CTx	Catheter	ITC	AMB + FLC	Survived							[18]
Myelofibrosis	CTx	Primary fungemia	MIF	L-AMB	Expired							[19]
Myelodysplastic syndrome	CTx	Catheter	MIF	FLC	Expired							[20]
AML	SCT	Primary fungemia	MIF	FLC	Expired							[20]
AML	CTx	Pneumonia	AMB + CAF	VRC	Expired	0.5	8	1			16	[20]
AML	CTx	Primary fungemia	MIF	VRC	Survived	1	32	1			16	[20]

AMB, amphotericin B deoxycholate; FLC, fluconazole; ITC, itraconazole; VRC, voriconazole; AML, acute myeloid leukemia; CAF, caspofungin; MIF, micafungin; SCT, stem cell transplantation; CTx, chemotherapy; L-AMB, liposomal amphotericin B; PSC, posaconazole.

Blank, not commented in the reference article.